We and others have previously demonstrated that sunitinib clinical activity for most GISTs is determined by the primary and secondary KIT mutations in those tumours.12,18 In the present study, we provide the first evidence of regorafenib spectrum of inhibition of imatinib-resistant KIT mutations. The gene discussed is KIT; the disease is neoplasm.